Ariyadamrongkwan J.Muanprasat C.Mahidol University2025-09-252025-09-252025-11-01Biomedicine and Pharmacotherapy Vol.192 (2025)07533322https://repository.li.mahidol.ac.th/handle/123456789/112266Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), a targeted therapy for the treatment of metastatic non-small cell lung cancer (NSCLC), improve patient outcomes compared to chemotherapy. Nevertheless, EGFR-TKIs are frequently associated with severe gastrointestinal toxicities, particularly diarrheas which often necessitate dose adjustments or treatment interruptions, thereby compromising therapeutic benefits. Current anti-diarrheal treatments are empirical and lack specificity, underscoring the need for a better understanding of the underlying mechanisms. This review highlights 3 key mechanisms underlying EGFR-TKI-induced diarrhea, emphasizing the role of ERBB signaling, including increased chloride secretion, enhanced intestinal epithelial permeability, and alterations in gut microbiota, which collectively contribute to the pathophysiology of diarrheas. The mechanisms contributing to diarrheas are discussed across different EGFR-TKI generations, with attention to their distinct receptor targets and the associated clinical prevalence of diarrheas. Potential therapeutic strategies are also categorized based on these underlying mechanisms, offering insights for effective management of EGFR-TKI-induced diarrheas.Pharmacology, Toxicology and PharmaceuticsReviewSCOPUS10.1016/j.biopha.2025.1185622-s2.0-10501630615319506007